Cancer Treatment in Türkiye: A Comprehensive Guide for International Patients

Cancer is not one disease. Even two tumours starting in the same organ can differ in cell type, stage, molecular profile, growth pattern and sensitivity to treatment. Before travelling to Türkiye, the first questions should therefore be “What exactly is the diagnosis, is the stage correct and what is the purpose of the proposed treatment?” rather than simply “Which hospital is best?”.

Treatment may aim to cure, lower the risk of recurrence, control disease, relieve symptoms or protect quality of life. The aim, likely benefit, limitations and side effects should be stated clearly at every stage.

Emergency warning: During active cancer treatment, do not wait for a routine appointment if you develop a temperature of 38°C or higher, shaking chills, breathlessness, uncontrolled bleeding, new confusion, severe pain, repeated vomiting, sudden weakness or one-sided leg swelling. Seek urgent medical assessment. The emergency number in Türkiye is 112.

Content review date: 18 August 2026. This guide provides general information; it is not a diagnosis, personalised treatment recommendation or outcome guarantee. An authorised oncology team must tailor the plan.

Which cancer treatments are available in Türkiye?

The US National Cancer Institute (NCI) explains that many people receive a combination of surgery, medicines and radiotherapy, depending on cancer type and extent. The newest or most expensive treatment is not better when the tumour biology does not support it.

First step: confirm the pathology

Pathology is the foundation of a cancer plan. A useful report should identify, where applicable, the site of origin, histological subtype, grade, margins, lymphovascular involvement and relevant immunohistochemical or molecular findings.

For an international second opinion, the centre may request:

• The complete pathology report;

• Stained slides and a paraffin block or unstained slides;

• Biopsy site and procedure note;

• Immunohistochemistry results;

• Raw reports from previous molecular/genetic tests;

• Surgical specimen and lymph-node details.

The NCI pathology guide notes that slides or a paraffin block can be requested for a second opinion and results may be reviewed together by a tumour board. Before shipping material, confirm the recipient’s instructions, customs requirements, tracking, liability and return process in writing.

Why might staging need review?

Stage describes where the cancer is and how far it has spread. Original scans may be re-read, or missing and outdated tests repeated before treatment. Take the actual DICOM images, not only PDF reports, to reduce unnecessary duplication.

Depending on the cancer, staging may involve:

• Contrast-enhanced CT or MRI;

• PET/CT or, in selected settings, PET/MRI;

• Ultrasound, mammography or endoscopy;

• Bone scan;

• Bone-marrow aspiration/biopsy;

• Tumour markers and organ-function testing;

• Performance status, nutrition and comorbidity assessment.

Not every patient needs PET/CT. A test should have a reasonable chance of changing management and be supported for that cancer type.

When are biomarker and molecular tests needed?

Biomarker testing examines genes, proteins or other tumour features. Some targeted treatments and immunotherapies work only when a relevant biomarker is present. The test is selected according to cancer type, stage, tissue availability and previous therapy.

The NCI biomarker guide explains that testing can guide treatment, but not every detected change is actionable. A variant of uncertain significance is not, by itself, an indication for a drug.

It is also important to distinguish:

• Tumour/somatic testing, which looks for changes acquired in cancer cells;

• Inherited/germline testing, which looks for changes present from birth and potentially relevant to relatives.

Possible inherited findings require clinical genetics input and appropriate counselling. Ask about test scope, specimen, laboratory accreditation, turnaround time, quality limitations and access to the complete report or raw data.

Why does a multidisciplinary tumour board matter?

Cancer planning should not be the decision of a single specialty. Depending on the tumour, the board may include:

• Medical oncologist;

• Surgical oncologist or organ-specific surgeon;

• Radiation oncologist;

• Pathologist and radiologist;

• Nuclear-medicine physician;

• Haematologist and transplant team;

• Clinical geneticist;

• Interventional radiologist;

• Palliative care, pain, nutrition, psycho-oncology and rehabilitation professionals.

The board brings diagnosis, stage, treatment sequence, resectability, biomarkers, likely benefit, toxicity and patient preferences together. The answer to “surgery, medicines or radiation first?” varies fundamentally by cancer.

Cancer surgery

Surgery can be a central treatment for a solid tumour confined to a region. It may aim to remove all cancer, establish diagnosis and stage, reduce tumour bulk or relieve symptoms. The NCI describes surgery as a local treatment and notes that it is not appropriate for every cancer that has spread.

The surgical proposal should state:

• Why an open, laparoscopic or robotic approach is suggested;

• Whether an organ-preserving alternative is reasonable;

• The lymph-node plan;

• The surgeon’s experience with comparable cases;

• Intensive care, blood-bank and reconstruction support;

• Use of frozen-section pathology where relevant;

• Possibility of a permanent stoma or functional loss;

• How final pathology will determine additional therapy.

Robotic surgery is an instrument platform, not a guarantee of better cancer control. Operator experience, patient selection and oncological principles matter more than the device label.

Radiotherapy

Radiation may be delivered through IMRT, VMAT, stereotactic body radiotherapy (SBRT), stereotactic radiosurgery (SRS), brachytherapy or proton therapy. These are not interchangeable and not every technique is needed for every tumour.

A radiation plan should specify:

• Treatment intent and target volume;

• Total dose, number of fractions and calendar;

• Simulation and immobilisation method;

• Technique and why it was selected;

• Dose constraints for nearby organs;

• Whether concurrent chemotherapy is required;

• Weekly review and side-effect support;

• How long the patient must remain in Türkiye.

Radiotherapy may require daily sessions over several weeks. Changing countries midway can be technically and clinically difficult. Even when DICOM-RT files are transferable, the receiving centre is responsible for reviewing and validating the plan and cumulative dose.

Chemotherapy and other systemic treatments

Systemic treatment travels through the bloodstream and can affect the whole body. In addition to chemotherapy, it includes targeted therapy, immunotherapy, hormone therapy and some radiopharmaceuticals.

The written protocol should include:

• Generic names and doses of all medicines;

• Intravenous, oral or other route;

• Number and dates of cycles;

• Neoadjuvant, adjuvant, curative or palliative purpose;

• Criteria for dose reduction or delay;

• Medicines to prevent nausea, infection and other side effects;

• Blood and organ-function tests before each cycle;

• Whether the same protocol can continue in the home country.

Immunotherapy is not a harmless “immune-boosting infusion”. It can cause immune inflammation of the lungs, bowel, liver, thyroid, pituitary and other organs. Targeted drugs should be used only when the relevant target and clinical indication are established.

Stem-cell transplantation and blood cancers

Autologous or allogeneic stem-cell transplantation may be considered for selected leukaemias, lymphomas, myeloma and other conditions. Transplant care includes conditioning treatment, infection prevention, blood-product support, isolation, graft-versus-host disease surveillance and long-term follow-up—not merely infusion of cells.

For allogeneic transplant, donor matching, cell source, donor screening, centre volume and accreditation matter. International patients should clarify the expected stay, nearby accommodation, caregiver requirement, readmission policy and haematology support at home before treatment.

How should treatment intent be described?

Promises of “100% cure”, “guaranteed result” or “no side effects” are not credible. Survival statistics do not guarantee an individual result and should be explained in the context of comparable stage, biology and health.

Step-by-step pathway for an international patient

1. Secure record transfer

Send pathology, laboratory results, operative notes, treatment summaries and DICOM images through a secure route. A one-page chronological clinical summary can speed review.

2. Pathology and imaging second opinion

Slides/blocks and scans are re-reviewed when the result could alter treatment. “The diagnosis was accepted” is not the same as “the material was independently reviewed”.

3. Tumour board and written options

Obtain the treatment intent, alternatives, sequence, duration, biomarkers, expected benefit and important toxicities in writing. If treatment starts in Türkiye and continues at home, the two clinical teams should communicate before the first cycle.

4. Face-to-face assessment in Türkiye

Examination, performance status, nutrition, organ function and selected tests may be repeated. New information can change or postpone the plan; this is part of safe practice.

5. Informed consent and treatment

Consent should cover intent, reasonable alternatives, common and serious adverse effects, fertility, blood products, possible intensive care and the right to decline, in a language the patient understands.

6. Discharge and cross-border handover

Collect pathology and molecular reports, imaging, operative/treatment summaries, delivered doses, implant details, medicine list, side-effect plan, emergency contacts and dates for the next cycle or review.

How should you compare hospitals and clinicians?

• A named team with expertise in the relevant cancer;

• A multidisciplinary tumour board;

• Quality-assured pathology, molecular diagnostics and radiology;

• Capacity to coordinate surgery, radiation and systemic therapy;

• 24-hour emergency, intensive care, blood-bank and infection support;

• Safe chemotherapy preparation and administration standards;

• Radiotherapy quality assurance and qualified medical physics;

• Clinical pharmacy, nutrition, pain, psycho-oncology and palliative care;

• Protocols for complications, readmission and treatment delay;

• Consent, interpreting and complete records in a language you understand;

• A genuine handover and follow-up plan after returning home;

• Current international health-tourism authorisation and accreditation/certification.

The Turkish Ministry of Health Health Tourism Department publishes current lists of authorised healthcare facilities and intermediary organisations. Its 2026 notices require specified authorised facilities to complete the relevant TÜSKA accreditation or certification pathway by 31 December 2026. Verify the latest official entry before booking.

What should an itemised quotation include?

A single “cancer package” is often inadequate. The quotation should separate:

• Initial consultation, second opinion and tumour board;

• Pathology review, immunohistochemistry and molecular tests;

• Imaging, laboratory and anaesthesia assessment;

• Surgery, surgeon, theatre, intensive care and ward days;

• Radiation simulation, planning, technique and total fractions;

• Generic drug names, dose, cycles and administration fees;

• Brand or biosimilar status of targeted/immunotherapy medicines;

• Port/catheter, blood products and supportive medicines;

• Policy for complications, readmission, delays and extra cycles;

• Interpreter, transfer, accommodation and companion;

• Post-treatment review, imaging and remote follow-up;

• Return of pathology material and medical records.

Inclusion of a drug in the first cycle does not mean it is covered throughout treatment. Obtain currency, tax, quotation validity, cancellation, postponement and refund terms in writing. Confirm whether insurance covers planned cancer care, side effects and medical evacuation.

What should you know about clinical trials?

A clinical trial is not the same as established standard treatment. The phase, purpose, eligibility, randomisation, possibility of placebo, study drug, standard care, additional tests and travel costs must be explained.

The NCI clinical-trials guide explains that participation is voluntary and withdrawal remains possible after signing consent. Sponsor funding does not necessarily make standard care, travel and accommodation free. Verify ethics approval, trial-registration number, sponsor and which costs are covered.

Travel and flying during cancer treatment

Cancer and its treatment can increase infection, anaemia, bleeding, dehydration and clot risk. Fitness to fly depends on treatment type, recent blood count, oxygen need, recent surgery, venous catheter, brain or lung involvement and journey length.

The CDC lists active cancer or recent cancer treatment among factors that increase clot risk during long travel. An aisle seat, movement and hydration may help selected people, but aspirin, anticoagulants or compression stockings should not be started without clinical advice.

Long travel may need to be avoided during the expected low-white-cell period after chemotherapy. Use flexible tickets, consider a companion, stay near the treating centre and know which emergency hospital will receive you.

Side effects and supportive care

Depending on treatment, side effects can include:

• Infection and neutropenia;

• Anaemia, low platelets and bleeding;

• Nausea, vomiting, diarrhoea or constipation;

• Mouth ulcers and swallowing difficulty;

• Fatigue, weight loss and malnutrition;

• Hair, skin and nail changes;

• Neuropathy and numbness;

• Heart, lung, kidney, liver or endocrine toxicity;

• Lymphoedema and impaired mobility;

• Fertility, sexual health, sleep, anxiety and depression concerns.

Supportive and palliative care are not restricted to the end of life. They can address pain, nutrition, nausea, psychological distress and functional loss alongside active cancer treatment. Discuss sperm, egg or embryo preservation before treatment that may affect fertility.

Which symptoms require urgent assessment?

The NCI warns that infection during cancer treatment can be life-threatening and that a temperature of 38°C or higher requires prompt contact with the oncology team. Do not mask fever with paracetamol/acetaminophen or ibuprofen before seeking instructions.

Also seek urgent help for:

• New breathlessness, chest pain or coughing blood;

• Sudden one-sided leg swelling, pain or discolouration;

• Uncontrolled bleeding or black stools;

• Confusion, seizure, new weakness or severe headache;

• Inability to retain fluids, repeated vomiting or markedly reduced urine;

• Severe abdominal pain, distension and inability to pass stool/gas;

• Redness, discharge or rapidly increasing pain around a catheter or wound;

• New diarrhoea, jaundice, cough or visual changes during immunotherapy.

Call 112 in Türkiye or the local emergency number elsewhere. Do not wait for an intermediary to respond in an emergency.

How can Clinicly Medical Tourism help?

Clinicly Medical Tourism can coordinate secure transfer of pathology, imaging and medical records to suitable centres; comparison of second opinions and tumour-board options; written treatment scopes and quotations; appointments, interpreting, transfers, accommodation and cross-border communication.

Clinicly is not the treating hospital and does not replace medical assessment. Diagnosis, stage, treatment intent, medicines and doses, surgery/radiation plan, trial eligibility, fitness to fly and complication management remain the responsibility of the licensed clinical team and healthcare facility. You can also review Clinicly’s patient guides for planning care in Türkiye.

Frequently asked questions

Can I travel to Türkiye only for a second opinion?

Yes. Some files can be reviewed remotely; if pathology material, examination or new testing is needed, an in-person visit can be planned.

Should the pathology be reviewed again?

A second pathology opinion can be valuable when diagnosis, subtype or biomarker results could change treatment. Ask whether slides and blocks were actually reviewed.

Does every patient need a broad genomic panel?

No. Testing should follow cancer type, stage and a meaningful treatment question. Not every variant is a drug target.

Is immunotherapy better than chemotherapy?

Not universally. Suitability depends on tumour type, stage, biomarkers, previous therapy, autoimmune disease and organ risks.

Is robotic surgery more successful?

A robot is a surgical platform. Outcomes depend on selection, surgeon experience, resectability and adherence to oncological principles.

Is proton therapy suitable for everyone?

No. It may reduce healthy-tissue dose in selected cases, but it is not clinically superior to modern conventional radiation for every tumour. Request a comparative plan.

Can treatment start in Türkiye and continue at home?

Sometimes. Drug availability, approval, matching protocol, monitoring and a home oncologist willing to assume care must be confirmed before treatment starts.

How long must I stay in Türkiye?

A second opinion may take days; surgery and recovery weeks; radiotherapy several weeks; and stem-cell transplant months. The individual plan determines duration.

Do I need a companion?

It is strongly advisable for major surgery, transplant, intensive systemic treatment, children, older adults and patients with mobility or language barriers. Some transplant centres require one.

What happens if treatment fails or side effects develop?

Ask in writing how response will be measured, when dose changes or second-line treatment apply, how urgent admission works and which additional costs may arise.

Conclusion: accurate diagnosis, correct sequence and continuous care

Türkiye offers centres in cancer surgery, radiation oncology, medical oncology, haematology, nuclear medicine and supportive care. A safe plan places pathology accuracy, staging, evidence-based biomarkers, tumour-board decisions and long-term follow-up ahead of a fast appointment or single package price.

Obtain the treatment purpose, alternatives, drug or implant details, side-effect plan and emergency pathway in writing. A multi-cycle programme begun in Türkiye may be interrupted if no team at home has agreed to assume care. Travel coordination must not replace clinical responsibility.

Medical notice: This guide is not a diagnosis, personal recommendation or cure guarantee. Cancer and its treatments can cause infection, bleeding, clots, organ injury, infertility, permanent functional loss and death. Seek emergency care where you are for fever, breathlessness, chest pain, confusion or uncontrolled bleeding.